Renalytix raises $14M through AIM placing and retail offer
What's the deal? RenalytixDealroom has a profile for this one. Try Dealroom →, a kidney-disease diagnostics company listed on London's AIM market, has raised roughly £10.5 million ($14.2 million) in gross proceeds. The total combines a placing, a subscription, and a WRAP Retail Offer, the company said on September 8, 2026.
The breakdown: The placing and subscription accounted for £10.1 million, while the WRAP Retail Offer added £380,142.12 at an issue price of £0.06 per ordinary share. Renalytix proposes to allot 6,335,707 retail offer shares.
Who's backing it: VenHedge Capital Partners committed US$2.25 million (£1,661,988), and its affiliate Feynman Point Asset Management Master FundDealroom has a profile for this one. Try Dealroom → put in $500,000 (£369,331) directly rather than through VenHedge. Together the two contributed US$2.75 million.
Why now? Of the £10.5 million total, £3.9 million is conditional on shareholders approving resolutions at a general meeting set for September 28, 2026. Dealings in the first tranche placing shares were expected to begin on AIM the same day the result was announced.
The signal: As a post-IPO equity raise, the deal reflects how listed small-caps lean on placings and retail offers to top up capital between milestones — with a share of the proceeds hinging on investor sign-off.
Read more: investegate.co.uk
Image credit: euthman
